NCT06202872Completed
Memory Enhancement Using Transcranial Alternating Current Stimulation
Source: ClinicalTrials.gov · Last updated 2 Jun 2026
Brief summary (registry, in English)
The 32 million Alzheimer's disease (AD) and 69 million prodromal AD patients worldwide contribute to a large economic burden. Effective and safe therapies that slow or prevent the progression from mild cognitive impairment (MCI) to AD are therefore of high priority. Transcranial alternating current stimulation (tACS) is a safe and patient-friendly non-invasive brain stimulation technique that serves as a potential candidate for reducing and/or slowing cognitive impairment. Application of tACS in the gamma frequency range, specifically around 40 Hz, has been studied in patients with AD and MCI due to AD. In these patients, a single session of 40 Hz tACS at the precuneus showed to improve episodic memory and to increase gamma power, as measured with electroencephalography. These findings will be replicated in the current study in patients with MCI due to AD, using magnetoencephalography (MEG) recorded before, during and after tACS. In this way, brain activity and network changes that underlie this improvement in episodic memory can be studied with greater temporal and spatial detail.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 26 (actual)
- First submitted
- 22 Dec 2023
- Start date
- 15 Nov 2024
- Primary completion date
- 28 Apr 2026
- Lead sponsor
- Amsterdam UMC, location VUmc
- Diseases
- Alzheimer disease
- NCT number
- NCT06202872
What you commit to
- Study type: Interventional
- Participants enrolled: 26
- From 15 Nov 2024 to the primary completion date, 28 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Intensive use of psychoactive medication
Other illness
- Suffering from serious neurological, psychiatric or somatic comorbidity
- Suffering from epileptic seizures or severe claustrophobia
- Having a cardiac pacemaker, internal cardiac defibrillator or other intracorporeal device that interferes with MEG recordings
Who the study is looking for
- Recent (not more than 6 months ago) amnestic MCI diagnosis, which consensus is obtained in a multidisciplinary meeting after an extended multidisciplinary test battery at the memory clinic, including confirmation of AD pathology with cerebrospinal fluid biomarkers: abnormal p-tau/Aβ42 ratio of \> 0.023
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Amsterdam UMC, The Netherlands Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.